awmsg logo

teriparatide (Forsteo®)

Reference No. 304

Publication date:

Appraisal information

teriparatide (Forsteo®) 20 micrograms/80 microlitres solution for injection

Company: Eli Lilly & Co Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: 09/06/2004
Submission Type: Full Submission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 30/09/2004

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA87) NICE GUIDANCE ISSUED JANUARY 2005 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of teriparatide (Forsteo®) within NHS Wales. It has been agreed that: (i) treatment with teriparatide (Forsteo®) within NHS Wales should be supported for the treatment of established severe osteoporosis in post menopausal women at a quadrupled risk for another osteoporotic fragility fracture; (ii) treatment should be initiated and supplied from secondary care for the full treatment course; and (iii) although not a prerequisite of support, AWMSG would wish to see a register established for long term safety follow up of patients treated with teriparatide (Forsteo®).
Final Appraisal Recommendation (FAR)